世界の巣状分節性糸球体硬化症(FSGS)治療市場規模・現状・予測(2021年-2027年)

• 英文タイトル:Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size, Status and Forecast 2021-2027

Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size, Status and Forecast 2021-2027「世界の巣状分節性糸球体硬化症(FSGS)治療市場規模・現状・予測(2021年-2027年)」(市場規模、市場予測)調査レポートです。• レポートコード:QYR2104Z2418
• 出版社/出版日:QYResearch / 2021年4月10日
• レポート形態:英文、PDF、95ページ
• 納品方法:Eメール(納期:3日)
• 産業分類:医療
• 販売価格(消費税別)
  Single User¥425,100 (USD3,900)▷ お問い合わせ
  Multi User/Five User¥637,650 (USD5,850)▷ お問い合わせ
  Enterprise License(同一法人内共有可)¥850,200 (USD7,800)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
QYResearch社発行の本調査資料では、巣状分節性糸球体硬化症(FSGS)治療のグローバル市場(2016年~2027年)について調べ、市場動向、主要企業の市場シェア、種類別市場規模(薬物療法、透析、腎臓移植)、用途別市場規模(一次FSGS、二次FSGS)、主要地域別市場規模(北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等)、関連企業情報などを掲載しています。
・市場概要
・巣状分節性糸球体硬化症(FSGS)治療の市場動向
・企業の競争状況、市場シェア
・巣状分節性糸球体硬化症(FSGS)治療の種類別市場規模(薬物療法、透析、腎臓移植)
・巣状分節性糸球体硬化症(FSGS)治療の用途別市場規模(一次FSGS、二次FSGS)
・巣状分節性糸球体硬化症(FSGS)治療の北米市場規模2016-2027(アメリカ、カナダ)
・巣状分節性糸球体硬化症(FSGS)治療のヨーロッパ市場規模2016-2027(ドイツ、フランス、イギリス等)
・巣状分節性糸球体硬化症(FSGS)治療のアジア市場規模2016-2027(日本、中国、韓国、インド、東南アジア等)
・巣状分節性糸球体硬化症(FSGS)治療の中南米市場規模2016-2027(メキシコ、ブラジル)
・巣状分節性糸球体硬化症(FSGS)治療の中東・アフリカ市場規模2016-2027(トルコ、サウジアラビア等)
・主要企業情報(B. Braun Melsungen、Medtronic、Pfizer、Complexa、Dimerix、Retrophin、Beckman Coulter Inc. (Danaher)、Boston Scientific Corporation、ChemoCentryx、Variant Pharmaceuticals)
・結論

Focal segmental glomerulosclerosis (FSGS) is a type of rare kidney disease that affects the kidney’s filtering system (glomeruli) resulting in proteinuria and serious scarring. Focal segmental glomerulosclerosis (FSGS) is usually fatal since it causes kidney failure within four to nine years followed by dialysis and then death. FSGS advances much more swiftly than diabetic nephropathy. Massive proteinuria, nephrotic syndrome, edema, hyperlipidemia, and hypoalbuminemia are some of the common symptoms of the disease. Risk factors include obesity, infection, sickle cell disease and reflux nephropathy.
The market for FSGS treatment is primarily driven by the increasing disease burden, rising focus towards rare diseases, and increased R&D activity. Geographical analysis shows that North America is expected to maintain its dominance in this market, particularly due to well-structured healthcare facilities, early adoption of therapies and diagnosis options, and better reimbursement policies, as compared to other regions.

Market Analysis and Insights: Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market
The global Focal Segmental Glomerulosclerosis (FSGS) Treatment market size is projected to reach US$ 414.3 million by 2026, from US$ 308.5 million in 2019, at a CAGR of 4.3% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Focal Segmental Glomerulosclerosis (FSGS) Treatment market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Focal Segmental Glomerulosclerosis (FSGS) Treatment market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Focal Segmental Glomerulosclerosis (FSGS) Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Focal Segmental Glomerulosclerosis (FSGS) Treatment market.

Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Scope and Market Size
Focal Segmental Glomerulosclerosis (FSGS) Treatment market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Focal Segmental Glomerulosclerosis (FSGS) Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Drug Therapy
Dialysis
Kidney Transplant

Segment by Application
Primary FSGS
Secondary FSGS

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
B. Braun Melsungen
Medtronic
Pfizer
Complexa
Dimerix
Retrophin
Beckman Coulter Inc. (Danaher)
Boston Scientific Corporation
ChemoCentryx

レポート目次

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Drug Therapy
1.2.3 Dialysis
1.2.4 Kidney Transplant
1.3 Market by Application
1.3.1 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Primary FSGS
1.3.3 Secondary FSGS
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Perspective (2016-2027)
2.2 Focal Segmental Glomerulosclerosis (FSGS) Treatment Growth Trends by Regions
2.2.1 Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Focal Segmental Glomerulosclerosis (FSGS) Treatment Historic Market Share by Regions (2016-2021)
2.2.3 Focal Segmental Glomerulosclerosis (FSGS) Treatment Forecasted Market Size by Regions (2022-2027)
2.3 Focal Segmental Glomerulosclerosis (FSGS) Treatment Industry Dynamic
2.3.1 Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Trends
2.3.2 Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Drivers
2.3.3 Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Challenges
2.3.4 Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Focal Segmental Glomerulosclerosis (FSGS) Treatment Players by Revenue
3.1.1 Global Top Focal Segmental Glomerulosclerosis (FSGS) Treatment Players by Revenue (2016-2021)
3.1.2 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue Market Share by Players (2016-2021)
3.2 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue
3.4 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Concentration Ratio
3.4.1 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue in 2020
3.5 Focal Segmental Glomerulosclerosis (FSGS) Treatment Key Players Head office and Area Served
3.6 Key Players Focal Segmental Glomerulosclerosis (FSGS) Treatment Product Solution and Service
3.7 Date of Enter into Focal Segmental Glomerulosclerosis (FSGS) Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Focal Segmental Glomerulosclerosis (FSGS) Treatment Breakdown Data by Type
4.1 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Historic Market Size by Type (2016-2021)
4.2 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Forecasted Market Size by Type (2022-2027)

5 Focal Segmental Glomerulosclerosis (FSGS) Treatment Breakdown Data by Application
5.1 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Historic Market Size by Application (2016-2021)
5.2 Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size (2016-2027)
6.2 North America Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Type
6.2.1 North America Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Type (2016-2021)
6.2.2 North America Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Type (2022-2027)
6.2.3 North America Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Type (2016-2027)
6.3 North America Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Application
6.3.1 North America Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Application (2016-2021)
6.3.2 North America Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Application (2022-2027)
6.3.3 North America Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Application (2016-2027)
6.4 North America Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Country
6.4.1 North America Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Country (2016-2021)
6.4.2 North America Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size (2016-2027)
7.2 Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Type
7.2.1 Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Type (2016-2021)
7.2.2 Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Type (2022-2027)
7.2.3 Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Type (2016-2027)
7.3 Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Application
7.3.1 Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Application (2016-2021)
7.3.2 Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Application (2022-2027)
7.3.3 Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Application (2016-2027)
7.4 Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Country
7.4.1 Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Country (2016-2021)
7.4.2 Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size (2016-2027)
8.2 Asia-Pacific Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Type
8.2.1 Asia-Pacific Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Type (2016-2027)
8.3 Asia-Pacific Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Application
8.3.1 Asia-Pacific Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Application (2016-2027)
8.4 Asia-Pacific Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Region
8.4.1 Asia-Pacific Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size (2016-2027)
9.2 Latin America Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Type
9.2.1 Latin America Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Type (2016-2021)
9.2.2 Latin America Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Type (2022-2027)
9.2.3 Latin America Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Type (2016-2027)
9.3 Latin America Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Application
9.3.1 Latin America Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Application (2016-2021)
9.3.2 Latin America Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Application (2022-2027)
9.3.3 Latin America Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Application (2016-2027)
9.4 Latin America Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Country
9.4.1 Latin America Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Country (2016-2021)
9.4.2 Latin America Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size (2016-2027)
10.2 Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Type
10.2.1 Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Type (2016-2027)
10.3 Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Application
10.3.1 Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Application (2016-2027)
10.4 Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Country
10.4.1 Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 B. Braun Melsungen
11.1.1 B. Braun Melsungen Company Details
11.1.2 B. Braun Melsungen Business Overview
11.1.3 B. Braun Melsungen Focal Segmental Glomerulosclerosis (FSGS) Treatment Introduction
11.1.4 B. Braun Melsungen Revenue in Focal Segmental Glomerulosclerosis (FSGS) Treatment Business (2016-2021)
11.1.5 B. Braun Melsungen Recent Development
11.2 Medtronic
11.2.1 Medtronic Company Details
11.2.2 Medtronic Business Overview
11.2.3 Medtronic Focal Segmental Glomerulosclerosis (FSGS) Treatment Introduction
11.2.4 Medtronic Revenue in Focal Segmental Glomerulosclerosis (FSGS) Treatment Business (2016-2021)
11.2.5 Medtronic Recent Development
11.3 Pfizer
11.3.1 Pfizer Company Details
11.3.2 Pfizer Business Overview
11.3.3 Pfizer Focal Segmental Glomerulosclerosis (FSGS) Treatment Introduction
11.3.4 Pfizer Revenue in Focal Segmental Glomerulosclerosis (FSGS) Treatment Business (2016-2021)
11.3.5 Pfizer Recent Development
11.4 Complexa
11.4.1 Complexa Company Details
11.4.2 Complexa Business Overview
11.4.3 Complexa Focal Segmental Glomerulosclerosis (FSGS) Treatment Introduction
11.4.4 Complexa Revenue in Focal Segmental Glomerulosclerosis (FSGS) Treatment Business (2016-2021)
11.4.5 Complexa Recent Development
11.5 Dimerix
11.5.1 Dimerix Company Details
11.5.2 Dimerix Business Overview
11.5.3 Dimerix Focal Segmental Glomerulosclerosis (FSGS) Treatment Introduction
11.5.4 Dimerix Revenue in Focal Segmental Glomerulosclerosis (FSGS) Treatment Business (2016-2021)
11.5.5 Dimerix Recent Development
11.6 Retrophin
11.6.1 Retrophin Company Details
11.6.2 Retrophin Business Overview
11.6.3 Retrophin Focal Segmental Glomerulosclerosis (FSGS) Treatment Introduction
11.6.4 Retrophin Revenue in Focal Segmental Glomerulosclerosis (FSGS) Treatment Business (2016-2021)
11.6.5 Retrophin Recent Development
11.7 Beckman Coulter Inc. (Danaher)
11.7.1 Beckman Coulter Inc. (Danaher) Company Details
11.7.2 Beckman Coulter Inc. (Danaher) Business Overview
11.7.3 Beckman Coulter Inc. (Danaher) Focal Segmental Glomerulosclerosis (FSGS) Treatment Introduction
11.7.4 Beckman Coulter Inc. (Danaher) Revenue in Focal Segmental Glomerulosclerosis (FSGS) Treatment Business (2016-2021)
11.7.5 Beckman Coulter Inc. (Danaher) Recent Development
11.8 Boston Scientific Corporation
11.8.1 Boston Scientific Corporation Company Details
11.8.2 Boston Scientific Corporation Business Overview
11.8.3 Boston Scientific Corporation Focal Segmental Glomerulosclerosis (FSGS) Treatment Introduction
11.8.4 Boston Scientific Corporation Revenue in Focal Segmental Glomerulosclerosis (FSGS) Treatment Business (2016-2021)
11.8.5 Boston Scientific Corporation Recent Development
11.9 ChemoCentryx
11.9.1 ChemoCentryx Company Details
11.9.2 ChemoCentryx Business Overview
11.9.3 ChemoCentryx Focal Segmental Glomerulosclerosis (FSGS) Treatment Introduction
11.9.4 ChemoCentryx Revenue in Focal Segmental Glomerulosclerosis (FSGS) Treatment Business (2016-2021)
11.9.5 ChemoCentryx Recent Development
11.10 Variant Pharmaceuticals
11.10.1 Variant Pharmaceuticals Company Details
11.10.2 Variant Pharmaceuticals Business Overview
11.10.3 Variant Pharmaceuticals Focal Segmental Glomerulosclerosis (FSGS) Treatment Introduction
11.10.4 Variant Pharmaceuticals Revenue in Focal Segmental Glomerulosclerosis (FSGS) Treatment Business (2016-2021)
11.10.5 Variant Pharmaceuticals Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Drug Therapy
Table 3. Key Players of Dialysis
Table 4. Key Players of Kidney Transplant
Table 5. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Regions (2016-2021) & (US$ Million)
Table 8. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Share by Regions (2016-2021)
Table 9. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 10. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Share by Regions (2022-2027)
Table 11. Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Trends
Table 12. Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Drivers
Table 13. Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Challenges
Table 14. Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Restraints
Table 15. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue by Players (2016-2021) & (US$ Million)
Table 16. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Share by Players (2016-2021)
Table 17. Global Top Focal Segmental Glomerulosclerosis (FSGS) Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Focal Segmental Glomerulosclerosis (FSGS) Treatment as of 2020)
Table 18. Ranking of Global Top Focal Segmental Glomerulosclerosis (FSGS) Treatment Companies by Revenue (US$ Million) in 2020
Table 19. Global 5 Largest Players Market Share by Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue (CR5 and HHI) & (2016-2021)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Focal Segmental Glomerulosclerosis (FSGS) Treatment Product Solution and Service
Table 22. Date of Enter into Focal Segmental Glomerulosclerosis (FSGS) Treatment Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Type (2016-2021) (US$ Million)
Table 25. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue Market Share by Type (2016-2021)
Table 26. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 27. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 28. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size Share by Application (2016-2021) & (US$ Million)
Table 29. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue Market Share by Application (2016-2021)
Table 30. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 31. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 32. North America Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Type (2016-2021) (US$ Million)
Table 33. North America Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 34. North America Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Application (2016-2021) (US$ Million)
Table 35. North America Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 36. North America Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 37. North America Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 38. Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Type (2016-2021) (US$ Million)
Table 39. Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 40. Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Application (2016-2021) (US$ Million)
Table 41. Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 42. Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 43. Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 44. Asia-Pacific Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Type (2016-2021) (US$ Million)
Table 45. Asia-Pacific Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Application (2016-2021) (US$ Million)
Table 47. Asia-Pacific Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Region (2016-2021) & (US$ Million)
Table 49. Asia-Pacific Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Region (2022-2027) & (US$ Million)
Table 50. Latin America Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Type (2016-2021) (US$ Million)
Table 51. Latin America Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 52. Latin America Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Application (2016-2021) (US$ Million)
Table 53. Latin America Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 54. Latin America Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 55. Latin America Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 56. Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Type (2016-2021) (US$ Million)
Table 57. Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Application (2016-2021) (US$ Million)
Table 59. Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 61. Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 62. B. Braun Melsungen Company Details
Table 63. B. Braun Melsungen Business Overview
Table 64. B. Braun Melsungen Focal Segmental Glomerulosclerosis (FSGS) Treatment Product
Table 65. B. Braun Melsungen Revenue in Focal Segmental Glomerulosclerosis (FSGS) Treatment Business (2016-2021) & (US$ Million)
Table 66. B. Braun Melsungen Recent Development
Table 67. Medtronic Company Details
Table 68. Medtronic Business Overview
Table 69. Medtronic Focal Segmental Glomerulosclerosis (FSGS) Treatment Product
Table 70. Medtronic Revenue in Focal Segmental Glomerulosclerosis (FSGS) Treatment Business (2016-2021) & (US$ Million)
Table 71. Medtronic Recent Development
Table 72. Pfizer Company Details
Table 73. Pfizer Business Overview
Table 74. Pfizer Focal Segmental Glomerulosclerosis (FSGS) Treatment Product
Table 75. Pfizer Revenue in Focal Segmental Glomerulosclerosis (FSGS) Treatment Business (2016-2021) & (US$ Million)
Table 76. Pfizer Recent Development
Table 77. Complexa Company Details
Table 78. Complexa Business Overview
Table 79. Complexa Focal Segmental Glomerulosclerosis (FSGS) Treatment Product
Table 80. Complexa Revenue in Focal Segmental Glomerulosclerosis (FSGS) Treatment Business (2016-2021) & (US$ Million)
Table 81. Complexa Recent Development
Table 82. Dimerix Company Details
Table 83. Dimerix Business Overview
Table 84. Dimerix Focal Segmental Glomerulosclerosis (FSGS) Treatment Product
Table 85. Dimerix Revenue in Focal Segmental Glomerulosclerosis (FSGS) Treatment Business (2016-2021) & (US$ Million)
Table 86. Dimerix Recent Development
Table 87. Retrophin Company Details
Table 88. Retrophin Business Overview
Table 89. Retrophin Focal Segmental Glomerulosclerosis (FSGS) Treatment Product
Table 90. Retrophin Revenue in Focal Segmental Glomerulosclerosis (FSGS) Treatment Business (2016-2021) & (US$ Million)
Table 91. Retrophin Recent Development
Table 92. Beckman Coulter Inc. (Danaher) Company Details
Table 93. Beckman Coulter Inc. (Danaher) Business Overview
Table 94. Beckman Coulter Inc. (Danaher) Focal Segmental Glomerulosclerosis (FSGS) Treatment Product
Table 95. Beckman Coulter Inc. (Danaher) Revenue in Focal Segmental Glomerulosclerosis (FSGS) Treatment Business (2016-2021) & (US$ Million)
Table 96. Beckman Coulter Inc. (Danaher) Recent Development
Table 97. Boston Scientific Corporation Company Details
Table 98. Boston Scientific Corporation Business Overview
Table 99. Boston Scientific Corporation Revenue in Focal Segmental Glomerulosclerosis (FSGS) Treatment Business (2016-2021) & (US$ Million)
Table 100. Boston Scientific Corporation Recent Development
Table 101. ChemoCentryx Company Details
Table 102. ChemoCentryx Business Overview
Table 103. ChemoCentryx Focal Segmental Glomerulosclerosis (FSGS) Treatment Product
Table 104. ChemoCentryx Revenue in Focal Segmental Glomerulosclerosis (FSGS) Treatment Business (2016-2021) & (US$ Million)
Table 105. ChemoCentryx Recent Development
Table 106. Variant Pharmaceuticals Company Details
Table 107. Variant Pharmaceuticals Business Overview
Table 108. Variant Pharmaceuticals Focal Segmental Glomerulosclerosis (FSGS) Treatment Product
Table 109. Variant Pharmaceuticals Revenue in Focal Segmental Glomerulosclerosis (FSGS) Treatment Business (2016-2021) & (US$ Million)
Table 110. Variant Pharmaceuticals Recent Development
Table 111. Research Programs/Design for This Report
Table 112. Key Data Information from Secondary Sources
Table 113. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Share by Type: 2020 VS 2027
Figure 2. Drug Therapy Features
Figure 3. Dialysis Features
Figure 4. Kidney Transplant Features
Figure 5. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Share by Application: 2020 VS 2027
Figure 6. Primary FSGS Case Studies
Figure 7. Secondary FSGS Case Studies
Figure 8. Focal Segmental Glomerulosclerosis (FSGS) Treatment Report Years Considered
Figure 9. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 10. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 11. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Share by Regions: 2020 VS 2027
Figure 12. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Share by Regions (2022-2027)
Figure 13. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Share by Players in 2020
Figure 14. Global Top Focal Segmental Glomerulosclerosis (FSGS) Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Focal Segmental Glomerulosclerosis (FSGS) Treatment as of 2020
Figure 15. The Top 10 and 5 Players Market Share by Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue in 2020
Figure 16. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue Market Share by Type (2016-2021)
Figure 17. Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Revenue Market Share by Type (2022-2027)
Figure 18. North America Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 19. North America Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Share by Type (2016-2027)
Figure 20. North America Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Share by Application (2016-2027)
Figure 21. North America Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Share by Country (2016-2027)
Figure 22. United States Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 23. Canada Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Share by Type (2016-2027)
Figure 26. Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Share by Application (2016-2027)
Figure 27. Europe Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Share by Country (2016-2027)
Figure 28. Germany Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. France Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. U.K. Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. Italy Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Russia Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Nordic Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Asia-Pacific Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Asia-Pacific Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Share by Type (2016-2027)
Figure 36. Asia-Pacific Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Share by Application (2016-2027)
Figure 37. Asia-Pacific Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Share by Region (2016-2027)
Figure 38. China Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Japan Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. South Korea Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Southeast Asia Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. India Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Australia Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Latin America Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Latin America Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Share by Type (2016-2027)
Figure 46. Latin America Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Share by Application (2016-2027)
Figure 47. Latin America Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Share by Country (2016-2027)
Figure 48. Mexico Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Brazil Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Share by Type (2016-2027)
Figure 52. Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Share by Application (2016-2027)
Figure 53. Middle East & Africa Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Share by Country (2016-2027)
Figure 54. Turkey Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. Saudi Arabia Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. UAE Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. B. Braun Melsungen Revenue Growth Rate in Focal Segmental Glomerulosclerosis (FSGS) Treatment Business (2016-2021)
Figure 58. Medtronic Revenue Growth Rate in Focal Segmental Glomerulosclerosis (FSGS) Treatment Business (2016-2021)
Figure 59. Pfizer Revenue Growth Rate in Focal Segmental Glomerulosclerosis (FSGS) Treatment Business (2016-2021)
Figure 60. Complexa Revenue Growth Rate in Focal Segmental Glomerulosclerosis (FSGS) Treatment Business (2016-2021)
Figure 61. Dimerix Revenue Growth Rate in Focal Segmental Glomerulosclerosis (FSGS) Treatment Business (2016-2021)
Figure 62. Retrophin Revenue Growth Rate in Focal Segmental Glomerulosclerosis (FSGS) Treatment Business (2016-2021)
Figure 63. Beckman Coulter Inc. (Danaher) Revenue Growth Rate in Focal Segmental Glomerulosclerosis (FSGS) Treatment Business (2016-2021)
Figure 64. Boston Scientific Corporation Revenue Growth Rate in Focal Segmental Glomerulosclerosis (FSGS) Treatment Business (2016-2021)
Figure 65. ChemoCentryx Revenue Growth Rate in Focal Segmental Glomerulosclerosis (FSGS) Treatment Business (2016-2021)
Figure 66. Variant Pharmaceuticals Revenue Growth Rate in Focal Segmental Glomerulosclerosis (FSGS) Treatment Business (2016-2021)
Figure 67. Bottom-up and Top-down Approaches for This Report
Figure 68. Data Triangulation
Figure 69. Key Executives Interviewed



• 英文レポート名:Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Size, Status and Forecast 2021-2027
• 日本語訳:世界の巣状分節性糸球体硬化症(FSGS)治療市場規模・現状・予測(2021年-2027年)
• レポートコード:QYR2104Z2418お問い合わせ(見積依頼・ご注文・質問)